Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia

Published:2020-12-24 Issue:12 Volume:11 Page:996-1007
ISSN:2218-4333
Container-title:World Journal of Clinical Oncology
language:
Short-container-title:WJCO

Author:

Stuckey Ruth,López-Rodríguez Juan Francisco,Sánchez-Sosa Santiago,Segura-Díaz Adrián,Sánchez-Farías Nuria,Bilbao-Sieyro Cristina,Gómez-Casares María Teresa

Publisher

Baishideng Publishing Group Inc.

Subject

Oncology

Reference64 articles.

1. Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

3. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

4. Chronic myeloid leukemia: reminiscences and dreams

5. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib;Indian Journal of Hematology and Blood Transfusion;2024-08-20

2. Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes;Journal of Cancer Research and Clinical Oncology;2024-04-11

3. The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia;Hematology Reports;2024-03-12

4. What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias;Hemato;2023-03-29

5. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial;Leukemia;2022-05-28